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Abstract
Background: Transient elastography (TE) is widely used for non-invasive assessment of liver fibrosis in HIV-HCV
co-infected patients. TE, however, cannot determine liver morphology. Acoustic radiation force impulse (ARFI)
imaging is a novel procedure enabling assessment of liver fibrosis during a conventional ultrasonographic
examination. This study evaluated the correlation between liver fibrosis measurements by TE and ARFI.
Methods: Each of 46 HIV-HCV patients underwent both ARFI and TE within 6 months. Patients were evaluated by
the “equivalent METAVIR” scoring system, using previously established cut-off values. Agreements between the ARFI
and TE scores were estimated by Kappa coefficients, with Kappa values ≥0.40, ≥0.60, and ≥0.80 defined as
moderate, good and very good agreement, respectively.
Results: ARFI and TE yielded "Equivalent Metavir" fibrosis scores of F1 in 26 and 31 patients, respectively; F2 in nine
and seven, respectively; F3 in three and two, respectively; and F4 in eight and six, respectively. The two methods
showed very good agreement in predicting overall stages [Kappa = 0.82] and for F ≥3 [Kappa = 0.80] and moderate
agreement in predicting significant fibrosis F ≥2 [Kappa = 0.50]. Morphologic ultrasound analysis concomitant to
ARFI detected two hepatocarcinomas.
Conclusions: ARFI showed promising results in the non-invasive assessment of liver fibrosis in HIV-HCV patients,
with liver fibrosis staging similar to that of TE. Moreover, ARFI can assess morphology and fibrosis during the same
session.
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Background
Since the introduction of highly active antiretroviral ther-
apy (HAART), chronic liver disease has emerged as one of
the leading causes of morbidity and mortality in HIV-HCV
co-infected patients [1,2]. Therefore, the management of
HCV-related liver disease has become a major challenge in
these patients [3].
Evaluation of liver fibrosis is considered essential to
the management of patients with chronic hepatitis C,
providing prognostic information and assisting in mak-
ing therapeutic decisions [4-7]. To date, liver biopsy has
been considered the gold standard to assess activity and
fibrosis in patients with chronic liver disease. Despite its
diagnostic utility, liver biopsy is limited because of its in-
vasiveness and cost, the risk of complications including
death, its poor acceptance by patients, the lack of avail-
ability of expert practitioners, and intra/inter-observer
variability [8-10]. In recent years, various non-invasive
methods for liver fibrosis assessment, have been devel-
oped, including serum biomarkers and elastography
techniques. Transient elastography (TE), real-time elas-
tography (RTE), acoustic radiation force impulse im-
aging (ARFI), and shear wave elastography are the most
frequent elastography techniques [11-15].
TE (FibroScan®) is currently the most extensively used
elastography technique in clinical practice [16-19]. Many
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prospective studies have evaluated the diagnostic perform-
ance of TE in staging liver fibrosis in patients with chronic
liver diseases, including chronic viral hepatitis C [11,20-22],
chronic viral hepatitis B [23], HIV–HCV co-infection
[24-26], alcoholic disease [27], and non-alcoholic fatty liver
disease [28]. Two meta-analyses found that TE is highly
accurate for the diagnosis of cirrhosis and advanced fibro-
sis [16,17], suggesting that TE may be used in place of bi-
opsy in most patients with chronic hepatitis C [18,29].
TE, however, has several drawbacks, including the re-
quirement for specific equipment that performs only elas-
tography, its ability to assess only the right liver, and its
inability to visually determine the site of measurement.
Moreover, ascites and obesity are limiting factors. ARFI
imaging has many advantages over TE. The technology
used for ARFI has been incorporated into a conventional
ultrasound system, allowing ultrasound analysis of liver
morphology at the same time. In addition, ARFI allows
elastography to be performed with a flexible metering box
at variable depths, enabling the exact localization of the
measurement site, and the examination can also be per-
formed in patients with ascites. ARFI measurements have
been found to correlate well with the stage of hepatic fibro-
sis [30-36]. However, to our knowledge, no study to date
has investigated the potential benefits of ARFI elastography
in evaluating fibrosis stage in HIV-HCV co-infected pa-
tients. This study therefore assessed the agreement be-




The study was approved by the institutional review board
of our University hospital. Between July 2009 and May
2012, HIV-HCV co-infected patients regularly followed up
at the HIV out-patient Clinic of the Department of Internal
Medicine and Infectious Disease of our hospital were pro-
spectively enrolled. All patients provided written informed
consent before inclusion.
The demographic, clinical and biological information of
all patients was obtained from their medical records. Fac-
tors included patient age, body mass index (BMI), alcohol
consumption, medications, specific antiretroviral drugs,
plasma HIV-RNA levels (IU/ml), complete blood counts,
absolute number of CD4+ T-cells (/mm3), plasma HCV-
RNA concentrations (IU/ml), and HCV genotype. Men
and women were considered heavy drinkers if they con-
sumed >3 and >2 glasses of alcohol per day, respectively.
Alanine aminotransferase (ALT), aspartate aminotransferase
(AST), γ-glutamyl transferase (GGT), alkaline phosphatase
(ALP), and bilirubin concentrations were also measured.
The presence of cirrhosis was evaluated in all patients
histologically and from imaging, clinical and biological
results [37,38]. Imaging findings indicative of cirrhosis
included small nodular and irregular livers with increased
echogenicity and/or a significant reduction in Doppler
flow in the portal circulation on ultrasound, CT, or MRI.
Quantitative ARFI imaging (Acuson S2000 Siemens)
and TE were performed by two different observers, with
each subject undergoing the two examinations no more
than 6 months apart. The physician performing the sec-
ond procedure was blinded to the results of the first
procedure.
Transient elastography (TE)
TE was performed in the right lobe of the liver through
the intercostal space as described [39,40]. Liver stiffness
was measured in a volume approximating a cylinder 1 cm
wide and 4 cm long, and at a depth between 25 and 65
mm. As suggested by the manufacturer, 10 successful
acquisitions were obtained for each patient in fasting
conditions. TE results were defined as very reliable
(IQR/M ≤0.10), reliable (0.10 < IQR/M ≤0.30 or IQR/
M >0.30 with LSE median <7.1 kPa) and poorly reliable
(IQR/M >0.30 with LSE median ≥7.1 kPa) [41]. Poorly re-
liable results were excluded. The median value for each
patient was expressed according to “equivalent Metavir” fi-
brosis scores using previously determined cut-off values
for HCV mono-infected patients of 7.1, 9.5 and 12.5 kPa
for liver fibrosis scores of F ≥ 2, F ≥3, and F = 4, respect-
ively [11].
ARFI examination
ARFI imaging is a method of quantifying the mechanical
properties of tissues, without manual compression, by
measuring the shear wave velocity induced by acoustic ra-
diation and propagating in the tissue. This quantitative
technique provides a single unidimensional measurement
of tissue elasticity like TE, although the measurement area
can be positioned on a two-dimensional B mode image.
The region is a 1 × 0.5-cm rectangle, which can be freely
moved in the two-dimensional B mode image to a max-
imum depth of 8 cm from the skin plane. Measurements
are expressed as m/s, indicating shear wave speed travel-
ing perpendicular to the shear wave source. The principle
of ARFI is described in Figure 1 [30,42,43].
All patients underwent quantitative elastographic ex-
aminations in fasting conditions with a Siemens Acuson
S2000TM ultrasound system (Siemens AG, Erlangen,
Germany) and an abdominal curved transducer (4C1),
using the virtual touch tissue quantification system.
The first step assessed liver morphology and echo-
structure, looking for cirrhosis, signs of portal hyperten-
sion and tumor lesions. In the second step, 10 ARFI mea-
surements of the right liver through the intercostal space
were performed by a single examination. To standardize
these examinations, an area of liver tissue free of large
blood vessels was chosen at a minimal distance of 2 cm
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below the liver capsule. ARFI measurements were expressed
in m/s as median (M), mean and standard deviation, and
interquartile range (IQR), with the IQR/M ratio used to evalu-
ate the variability of the measurements. An IQR/M<0.3 was
considered a homogeneous set of measurements. Median
ARFI value was expressed according to the ‘equivalent
Metavir’ score using previously determined cutt-off values
for HCV mono-infected patients of 1.34, 1.55, 1.80 m/s for
liver fibrosis scores of F ≥ 2, F ≥3, and F = 4, respectively [44].
Statistical analysis
Quantitative characteristics were expressed as mean (stand-
ard deviation), median (first-third quartile) and range, and
compared using non-parametric Wilcoxon statistics. Quali-
tative characteristics were expressed as frequencies and
proportions, and compared using Fisher’s exact test.
Correlations between TE and ARFI measurements were
estimated using Spearman’s correlation coefficient and its
two-sided 95% confidence interval (CI), as calculated with
Fisher's z transformation.
Agreements between “equivalent Metavir” fibrosis stages
on ARFI and TE were assessed by simple Kappa coeffi-
cients for predictions of F ≥ 3 or F ≥2, and F = 4, and
weighted Kappa coefficients for predictions of F1 to F4
Metavir scores; two-sided 95% CIs were also estimated.
Kappa values ≥0.60 and ≥0.80 were considered indicative
of good and very good agreement, respectively. Additional
analysis was performed in patients infected with HCV ge-
notypes 1 and 4, who usually have a poorer response than
patients infected with genotypes 2 and 3.
Quantitative and qualitative variables associated with
discordances between ARFI and TE staging were assessed
by the Wilcoxon test and Fisher’s exact test, respectively.
Only univariate analyses were performed because of the
small number of subjects.
Results
Characteristics of the study population
Of the 86 examinations, 40 were excluded because of
missing data (n = 8), too long delay (>6 months) between
ARFI and TE (n = 24) or repeated examinations for the
same patient (n = 8). When liver stiffness was measured
repeatedly in the same patient, only the measurement with
minimal delay between ARFI and TE was included in the
analysis. Valid results of both ARFI and TE were obtained
for 46 patients; their demographic and clinical and
biological characteristics are summarized in Table 1.
Of the 46 patients, 28 did not receive any treatment
for HCV, whereas the other 18 were treated with pegin-
terferon and ribavirin (SOC). At the time of ARFI, eight
had achieved a sustained virologic response, whereas the
other 10 had failed treatment. No patient received any
direct-acting antiviral agents (DAAs). Moreover, all 46
patients had received highly active antiretroviral therapy
(HAART), including 28 who received third-generation
protease inhibitors (PIs), three who received integrase
inhibitors (INIs), eight who received non-nucleoside re-
verse transcriptase inhibitors (NNRTIs), and seven who
received other treatment combinations (Table 1).
Ultrasound analysis allowed the detection of focal liver le-
sions in five patients, including two with hepatocellular car-
cinoma (HCC) and three with benign liver lesions. The two
HCCs presented with arterial hypervascularity and wash-
out in venous and delayed phase on dynamic enhanced
MRI [45]. Their diagnosis was confirmed by histologic
examination of biopsy specimens obtained just before liver
nodule radiofrequency. The three benign liver lesions were
diagnosed based on their tumor-specific vascularity patterns
in the arterial, portal, and late phases on dynamic enhanced
MRI, as described [46-48]. Imaging features were typical,
with liver biopsies not required to confirm their diagnosis.
ba
Figure 1 Principle or ARFI quantitative measurement. a) Schematic of principles of ARFI imaging in virtual touch quantification mode – b)
Example of a SWV measurement of the right liver. Transmission of a longitudinal acoustic pulse leads to tissue displacement, resulting in shear
wave propagation away from the region of excitation. The shear wave velocity is measured within a defined region of interest (ROI) using
ultrasound tracking beams laterally adjacent to the single push beam. The shear velocity is estimated in a graphically displayed ROI measuring
1 × 0.5 cm. The shear wave propagation velocity is proportional to the square root of tissue elasticity.
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Evaluation of liver fibrosis
The median delay between ARFI and TE in the 46 evalu-
ated patients was 10 days (range, 0–25 days). Median liver
stiffness on TE was 6.1 kPa (range 3.4–35.3 kPa) and me-
dian shear wave velocity (SWV) on ARFI was 1.29 m/s
(range 0.93–2.86 m/s). Median liver stiffnesses on TE in
patients with F1, F2, F3, and F4 fibrosis stages were 5.4
kPa (range 4.1–6.1 kPa), 7.2 kPa (range, 7.1–7.8 kPa), 11.6
kPa (range, 10.8–12.3 kPa) and 24.6 kPa (range, 18.0–27.7
kPa), respectively. Median SWVs on ARFI in patients with
F1, F2, F3 and F4 fibrosis stages were 1.15 m/s (range,
1.06–1.25 m/s), 1.44 m/s (range, 1.40–1.47 m/s), 1.60 m/s
(range, 1.58–1.61 m/s), and 2.25 m/s (range, 2.12–2.52 m/
s), respectively. Figure 2 shows a scatterplot of the rela-
tionship between median results on TE and ARFI.
Comparison of equivalent Metavir fibrosis scores on TE
and ARFI
Spearman correlation analysis showed that the correlation
coefficient between ARFI and TE measurements was 0.76
[95% CI, 0.61–0.86]. Table 2 shows the agreement between
TE and ARFI measurements, as determined by equivalent
Metavir fibrosis scores. Overall agreement between the
two methods was very good [concordance 69.6%, weighted
Kappa = 0.82; 95% CI = 0.70–0.95]. Agreement was also
very good for predicting severe fibrosis (≥F3) [concord-
ance 93.5%, Kappa = 0.80, 95% CI = 0.59–1.00], and was
moderate for predicting significant fibrosis (≥F2) [con-
cordance 76.1%, Kappa = 0.5, 95% CI = 0.25–0.75].
Of the 46 patients, 14 (30%) showed discordant Metavir
scores between the two methods, 11 in predicting F ≥ 2
and three in predicting F ≥ 3. ARFI yielded a higher fibro-
sis score than TE for 11 of these patients. As the discord-
ance was more important for predicting F ≥ 2, factors
possibly associated with these discordances were analyzed,
including age; sex; BMI; alcohol consumption; plasma
HCV-RNA levels; absolute CD4+ (/mm3) cells; HCV
genotype; increased serum AST, ALT, ALP, and GGT
(>2N) and bilirubin concentrations; steatosis; cirrhosis;
HIV and HCV treatment; and response to HCV treat-
ment. Only age was associated with the discordance be-
tween the two methods (p = 0.047) with older patients in
the discordant group. Discordance also tended to be
Table 1 Patient demographic and clinical characteristics
Demographics




BMI Median (Q1; Q3) 22.4 (19.8; 24.3)
Overweight (BMI > =25) n (%) 8 (17.4)
Chronic alcohol abuse n (%) 15 (34.1)
Cirrhosis n (%) 6 (13)
Child Pugh stage n 6
A n (%) 6 (100)
B, C, D n 0
HIV treatment
Protease inhibitors n (%) 28 (60.9)
Integrase inhibitors n (%) 3 (6.5)
Non-nucleoside RT inhibitors n (%) 8 (17.4)
Other treatment n (%) 7 (15.2)
HCV treatment
None, n (%) 28 (60.9)
Previous treatment failure n (%) 10 (21.7)
Previous sustained virologic response n (%) 8 (17.4)
Virology
HCV genotype n (%)
1-1a-1b 24 (59)
2-3-3a 9 (22)
4 41b-4a 8 (19)
ND 5 (10)
HCV RNA > 15 IU/ml n (%) 38 (83)
HCV RNA IU/ml (Q1; Q3) 1116144 (391800;
3680000)
Undetectable HIV RNA n (%) 40 (87)
CD4/mm3 (Q1; Q3) 576 (377; 833)
Liver blood test
Delay between ARFI and blood test days
(Q1; Q3)
0 (0; 1)
AST or ALT ≥2N n (%) 7 (15.6)
GGT and/or ALP ≥2N n (%) 15 (33.3)
Bilirubin ≥2N n (%) 10 (22.2)
US liver characteristics
Steatosis n (%) 3 (6.5)
Cirrhosis in US n (%) 6 (13)
US portal hypertension signs n (%) 2 (4.3)
US hepatomegaly n (%) 14 (30.4)
US focal liver lesion n (%) 5 (10.9)
Table 1 Patient demographic and clinical characteristics
(Continued)
ARFI characteristics
Median (Q1; Q3) (m/s) 1.29 (1.15; 1.55)
Min; Max 0.93; 2.86
TE characteristics
Median (Q1; Q3) (kPa) 6.1 (4.6; 7.2)
Min; Max 3.4; 35.3
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associated directly with hepatomegaly and inversely with
overweight, cytolysis, and cholestasis. No significant differ-
ence was found with HIV (p=0.22) and HCV(p=0.55)
treatment.
Similar results were observed in the subgroup of pa-
tients infected with HCV genotypes 1 and 4. Table 3
shows the agreement between TE and ARFI measure-
ments, as determined by equivalent Metavir fibrosis stage
classification, in these patients. Agreement between the
two methods was very good overall [concordance 65.6%,
weighted Kappa = 0.84; 95% CI = 0.71–0.96], very good in
predicting severe (F ≥3) fibrosis [concordance 93.8%,
Kappa = 0.83, 95% CI = 0.61–1.00], and moderate in pre-
dicting significant fibrosis (F ≥2) fibrosis [concordance
75%, Kappa = 0.51, 95% CI = 0.22–0.79].
Discussion
The correct evaluation of liver fibrosis in patients with
chronic liver disease, especially in those co-infected with
HIV and HCV, is of paramount importance for patient
management. The presence of significant fibrosis is an
indication for treatment, regardless of HCV genotype,
whereas the presence of cirrhosis is an indication for ini-
tiating a surveillance program for the early detection of
HCC and for esophageal varices.
To our knowledge, no study to date has used ARFI to
evaluate liver fibrosis in HIV-HCV co-infected patients
or compared the results of ARFI and TE in this popula-
tion. This pilot study, found that these two methods
yielded similar results. ARFI and TE showed very good
agreement in predicting overall fibrosis stage and stage
F ≥ 3. According to the literature, the two methods also
showed similar results in mono-infected patients and in
patients with other types of chronic liver disease. A meta-
analysis of nine studies showed that ARFI imaging had ex-
cellent diagnostic accuracy for the staging of liver fibrosis
in various chronic liver diseases; compared with liver bi-
opsy, ARFI was highly accurate in the diagnosis of fibrosis
Figure 2 Scatterplot of the relationship between median ARFI (m/s) and TE (kPa) measurements.
Table 2 Agreement between TE and ARFI fibrosis stage
classification according to “equivalent Metavir” fibrosis
scores
ARFI
F1 F2 F3 F4 TOTAL
TE F1 23 6 2 0 31
F2 3 3 1 0 7
F3 0 0 0 2 2
F4 0 0 0 6 6
TOTAL 26 9 3 8 46
Observed agreement: 69.6% 95% CI = [54.2–82.3].
Weighted Kappa coefficient: 0.82 95% CI = [0.70–0.95].
Table 3 Agreement between TE and ARFI fibrosis stage
classification according to “equivalent Metavir” fibrosis
stage in patients infected with HCV genotypes 1 and 4
ARFI
F1 F2 F3 F4 TOTAL
TE F1 13 5 1 0 19
F2 2 3 1 0 6
F3 0 0 0 2 2
F4 0 0 0 5 5
TOTAL 15 8 2 7 32
Overall proportion of agreement: 65.6% 95% CI [46.8–81.4].
Kappa: 0.84 95% CI [0.71–0.96].
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stage F ≥ 3 (AUROC= 0.91) and for the diagnosis of liver
cirrhosis (AUROC= 0.93) [44]. Moreover, an international
multicenter study of 911 HCV mono-infected patients
found that ARFI was highly accurate in the diagnosis of fi-
brosis stage F ≥ 3 (AUROC= 0.83) [49].
We observed a moderate agreement between the two
techniques for predicting F ≥ 2. Earlier studies also showed
that TE or ARFI was more accurate for predicting extreme
stages (F1 or F4) than moderate (F2) fibrosis. For example,
the AUROCs for ARFI were higher for predicting F=4
(0.84;0.95;0.91) than F≥ 2 (0.79;0.77;0.82) [30,33,49].
In addition, agreement between the TE and ARFI scores
was determined in patients infected by genotype 1 and 4
who usually have poorer response than patients infected
with genotype 2 and 3. Similarly, there was no difference in
concordance level between patients with genotypes 1 and 4
and those with other genotypes. The TE and ARFI methods
showed very good agreement in predicting overall fibrosis
stage and F ≥ 3 in patients with genotypes 1 and 4.
This study included a small number of patients (n = 46).
However, it was designed as a pilot study, with intraclass
correlation coefficients precise enough to draw conclusions
by comparing the lower limit of the 95% CIs with 0.6,
deemed to represent the lower limit of good agreement.
ARFI has several advantages compared with TE. TE has
been reported to have an average failure rate of 3.1% and
to be highly dependent on BMI. Moreover, TE measure-
ments were estimated to be unreliable in 15.8% of patients
in a very large study [19]. We found that ARFI examina-
tions were reliable in all patients, with no measurement
limitations due to overweight or the presence of ascites.
ARFI measurement depth can be adapted according to the
distance between the skin and liver capsule. In addition,
ARFI is an ultrasound-based elastography method, inte-
grated into a routine ultrasound machine, allowing simul-
taneous morphological and Doppler analysis of the liver,
screening for focal liver lesions and evaluation of liver fi-
brosis. Moreover, the presence of B mode allows ARFI
measurements to be localized to liver segments far from
the capsule and blood vessels. Ultrasound morphological
analysis of our patients identified cirrhosis in six patients
and focal liver lesions in five, including two HCCs. More-
over, the presence of HCC did not influence fibrosis evalu-
ation because ARFI measurements in non-tumoral liver
were performed at a distance (>3 cm) from the tumor. In-
deed, the visual control in B mode allowed the ROI to be
positioned to avoid specific areas, including tumors.
TE and ARFI showed a discrepancy in predicting fi-
brosis score in 30% of patients, especially in predicting
F ≥ 2. Apart from age, no factor was clearly associated
with these discrepancies. However, the study size was
not powered for this aim. Liver biopsy should have been
performed in patients with discordance, but was not ex-
cept in one patient, in whom ARFI, but not TE, agreed
with biopsy results. Moreover, when a discrepancy was ob-
served between the two techniques, it was not possible to
conclude whether TE or ARFI was more correct. These
discrepancies may be linked to the cut-off values used, as
these are not the same in all published studies. The TE
cut-off values we used [11] yielded similar results as other
cut-off values from a recent meta-analysis [17] (data not
shown). However, although meta-analyses have found TE
to be reliable in assessing liver fibrosis stage, irrespective of
etiology, most studies were performed in western patients
with HCV mono-infection. Thus, applying these cut-off
values to patients co-infected with HIV and HCV may re-
sult in discrepancies. To date, however, no ARFI cut-off
values have been determined for co-infected patients.
Finally, although liver biopsy has been considered the
gold standard for the assessment of liver fibrosis, we
elected to use non-invasive methods for comparison [12].
Fibrosis is heterogeneously distributed throughout the
liver, whereas a biopsy evaluates only 1/50000 of the total
volume of the liver. The likelihood of misdiagnosing a
fragment 2.5 cm in length has been estimated to be as
high as 25%, with the optimal size of a biopsy sample be-
ing 4 cm, which is difficult to obtain in daily practice [10].
Moreover, liver biopsy is an invasive and costly method,
with high risks of complications and intra-/inter-observer
variability. Thus, liver biopsy is increasingly replaced by
non-invasive methods, especially TE. Since TE is consid-
ered a reliable diagnostic modality in clinical practice, we
compared the results of ARFI with those of TE.
Conclusions
This pilot study showed good agreement between TE
and ARFI in evaluating liver fibrosis in HIV-HCV co-
infected patients, suggesting that ARFI may replace TE
in this population. In addition to being a new and prom-
ising sonography-based method for non-invasive assess-
ment of liver fibrosis, ARFI is cost effective, allowing
routine ultrasound examination and fibrosis assessment
during the same session.
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